Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
04 July, 2015 03:31 IST
Dr Reddys gets USFDA nod for Sildenafil tablets
Source: IRIS | 19 Nov, 2012, 09.43AM
Comments  |  Post Comment

Dr Reddys Laboratories, an integrated global pharmaceutical company,  announced that it has launched Sildenafil tablets (20 mg), a bioequivalent generic version of Revatio (Sildenafil) tablets in the US market.

It has received approval by the United States Food & Drugs Administration (USFDA) for ANDA Sildenafil tablets.

The Revatio brand had US sales of approximately USD 338.67 million for the most recent 12 months ending September 2012 according to IMS health.

Shares of the company gained Rs 16, or 0.91%, to trade at Rs 1,773.35. The total volume of shares traded was 755 at the BSE (9.32 a.m., Monday).



Dr Reddy`S Laboratories Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Shoppers Stop ties up with SAP hybris - 03-Jul-2015 16:48
Jindal Steel production climbs 38% in Apr-Jun'15 - 03-Jul-2015 16:09
SBI launches 'Project TATkal' to deliver home loan within 10 days - 03-Jul-2015 15:08
TVS Motor launches special edition 'TVS XL Super' - 03-Jul-2015 13:25
BHEL successfully achieves renovation, modernisation and uprating of 110 MW Unit - 03-Jul-2015 12:38
Persistent Systems acquires 100% stock of RGEN Solutions - 03-Jul-2015 12:05
L&T builds India's first 700mwe PHWR Nuclear Steam Generator - 03-Jul-2015 11:02
MCX inks MoU with Christ University - 03-Jul-2015 10:58
Infosys invests in Ireland following strategic partnership with AIB - 03-Jul-2015 10:55
ABB board approves to raise Rs 6 bn via NCDs - 03-Jul-2015 09:47
Spice Mobility arm acquires 26% stake in Creative Functionapps - 03-Jul-2015 09:12
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer